Sign up
Pharma Capital

Immunoprecise Antibodies expanding immunization services through recent growth in Europe

The company's advanced genetic immunization strategies are applicable in multiple species
1540838557_antibody2.jpg
The company's advanced genetic immunization strategies are applicable in multiple species

Antibody discovery group Immunoprecise Antibodies Ltd (CVE:IPA) says it's expanding its immunization services through recent growth in Europe, and announced a genetic immunization platform.

The company's advanced genetic immunization strategies are applicable in multiple species, including transgenics and across all discovery platforms, it said.

There is growing demand for therapeutic antibodies against challenging, conformation-sensitive drug targets.

Genetic immunization overcomes the  obstacles of difficult antigens making it an ideal immunization platform in therapeutic discovery campaigns.

Immunoprecise also announced Monday that it had settled $1.37 million of previously issued debentures by issuing 1.37 million units at a price of $1 per unit.

The purpose of the debt settlement is to shore up Immunoprecise's balance sheet by removing continuing debt obligations related to $1,377,000 of debentures

Shares in Toronto eased  1.2% to $0.77.

View full IPA profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.